Abituzumab Biosimilar - Research Grade

Human

CD51

>1mg/ml

Human IgG1 Kappa

https://www.imgt.org/mAb-DB/

ICH3002

P06756

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-integrin alphaV (CD51) antibody abituzumab, produced for research use only. It reproduces the antigen-binding specificity of the originator drug against the human integrin alphaV subunit, making it a useful reference reagent for studies of alphaV-integrin biology, ligand-blocking, and adhesion. Because it is supplied unconjugated and in low-endotoxin format (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg), it suits sensitive in-vitro assays and cell-based work where endotoxin can confound results. It is offered in bulk milligram-to-gram quantities to support screening cascades, positive and isotype-matched controls, cross-reactivity panels, and biosimilar or bioassay standardization. Typical uses include binding and neutralization characterization, comparison against candidate biologics, and preclinical model reagents. It is not the clinical drug and is not intended for human or veterinary use, diagnosis, or therapy. The originator abituzumab is a humanized anti-alphaV antibody; note the isotype listed on this card should be confirmed against your intended application. CD51 is the integrin alphaV subunit (gene ITGAV, UniProt P06756), a type I transmembrane glycoprotein that pairs with distinct beta subunits (beta1, beta3, beta5, beta6, beta8) to form a family of alphaV-class integrins. These heterodimers recognize the Arg-Gly-Asp (RGD) motif found in extracellular matrix and matricellular ligands including vitronectin, fibronectin, osteopontin, and the latency-associated peptide of TGF-beta. Through these interactions alphaV integrins mediate cell adhesion, migration, survival signaling, and, notably, activation of latent TGF-beta, linking them to angiogenesis, tissue fibrosis, and tumor progression. alphaVbeta3 and alphaVbeta5 are implicated in tumor angiogenesis and bone metastasis, while alphaVbeta6 and alphaVbeta8 drive TGF-beta activation relevant to fibrotic disease. Because a single antibody against the alphaV subunit can block multiple alphaV heterodimers simultaneously, CD51 is an attractive node for interrogating integrin-dependent adhesion and signaling in research settings.

ITGAV, CD51, MSK8, VNRA, VTNR, integrin subunit alpha V

Detects human CD51

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.